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            Breast cancer (BC) is one of the most common diagnosed malignancies in 
females. Although 90% of early diagnosed women are expected to survive for at least 5 
years, their quality of life is adversely affected by a cluster of symptoms which we 
collectively named “psychoneurological symptoms’’ (PN). Given that acquired telomere 
attrition has been speculated to be a causal factor in chronic diseases and the lack in 
	   viii	  
the literature of mechanisms giving rise to PN symptoms, this study was performed to 
assess telomere length using a chromosome-specific telomere assay before receiving 
chemotherapy and at the first chemotherapy. We showed significant telomere attrition 
on the short arm of chromosome 9. In addition, we showed a negative correlation 
between telomere length and depression. Furthermore, we evaluated several variables 
as predictors of the change in telomere length and showed that chemotherapy was 
predictive of shortened telomere length. Taken together, one can speculate that 
shortened telomeres could result in epigenetic alterations in the genes juxtaposed to the 
telomeric region, giving rise to the development and persistence of PN symptoms. 
Knowledge gained from this study will offer hope for the development of therapeutic 
interventions that could prevent undesirable side effects and ensure a better quality of 
life for patients with BC.    
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Chapter 1 
Introduction  
            In 2009 the Nobel Prize in Physiology or Medicine was jointly awarded to 
Elizabeth Blackburn, Carol Greider and Jack Szostak “for the discovery of how 
chromosomes are protected by telomeres and the enzyme telomerase”. The structure of 
the telomere was first recognized by Hermann Muller and Barbara McClintock through 
their studies in Drosophila (Muller, 1938) and maize (McClintok, 1941). Muller 
concluded that a special structure at the end of the chromosome was required for its 
integrity and first coined the term ‘telomere’. Three years later, McClintock (1941) 
proposed that telomeres stabilize chromosome ends and prevent them from being 
recognized as DNA double strand breaks.  
            As a result of intensive research that has been completed since these 
pioneering studies, much is now known about telomeres. Telomeres can now be more 
precisely described as being comprised of non-coding tandem arrays of a “TTAGGG” 
DNA sequence that are located at the terminal ends of all vertebrate chromosomes 
including those of humans (Moyzis, et al., 1988). A G-rich single stranded 3’ overhang is 
present at the end of human telomeres and is thought to be important for telomere 
function (Makarov et al., 1997, Wright et al., 1997). This single stranded 3’ overhang 
folds back on itself forming a large loop structure called a telomere loop, or T-loop that 
has a shape similar to that of a paper clip. The telomere is stabilized by a six-protein 
complex called shelterin, which includes Telomeric Repeat binding Factor 1 and 2 
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(TRF1 andTRF2), Protection of Telomeres 1(POT1), TRF1 and TRF2 Interacting 
Nuclear protein 2(TIN2), the human ortholog of the yeast Repressor/Activator protein 
1(Rap1) and TPP1. Shelterin components specifically localize to the telomere due to the 
recognition of TTAGGG repeats by three of its components: TRF1 and TRF2 recognize 
the duplex part of telomeres and bind to it, whereas POT1 recognizes the single 
stranded repeat sequence in the 3’ overhang localized within the T-loop structure 
(specifically within the “displacement” or D-loop). TIN2, TPP1, Rap1 and POT1 are 
recruited to the telomere by TRF1 and TRF2 (Palm & de Lange, 2008). 
            In 1961, Leonard Hayflick and Paul Moorhead discovered that cells cultured in 
vitro undergo a limited number of divisions, a phenomenon which is now known as 
replicative senescence or the “Hayflick limit”, and suggested the existence of a cellular 
counting mechanism (Hayflick & Moorhead, 1961). Furthermore, they observed the 
presence of two broad classes of cells, normal mortal cell strains and immortal cancer 
cell lines (reviewed in Hayflick, 1998). Their discovery challenged a central dogma of 
the time that supported the belief that cultured cells could divide indefinitely in vitro, with 
any culture failures being attributable simply to a lack of technical expertise. 
            By combining the knowledge that the properties of DNA replication prevent cells 
from fully replicating the ends of linear chromosomes (Watson, 1972) with the 
observation that normal cells have a limited capability to replicate, Olovnikov proposed 
his theory of marginotomy (1973). It has been reported that he developed this 
hypothesis while waiting for a subway train in Moscow. As he heard the train coming, he 
imagined the train, and specifically the engine, being the DNA polymerase and the track 
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being the DNA. The engine (DNA polymerase) would not be able to replicate the first 
segment of DNA (the track) because it lay exactly underneath the engine. It seemed 
unlikely that with each cell division a DNA segment containing important genes was lost. 
Therefore, Olovnikov reasoned that the repeated non-coding telomeric nucleotide 
sequences act as a buffer to protect gene coding sequences. He correctly speculated 
that with each round of cell division a portion of the telomere “buffer” would be lost, and 
that the length of the telomeric “buffer” could be important for determining a cell’s ability 
to proliferate (reviewed in Hayflick, 1998; Greider, 1998).  
             In testing the hypothesis that telomere length was related to the proliferative 
capacity of cultured cells, Harley, et al (1990) found that the mean telomere length was 
decreased by two to three kilobase pairs (kbp) during the entire life time of multiple 
strains of cultured human fibroblasts. In contrast immortal cell lines, identified by 
Hayflick, appeared to avoid telomere shortening with serial passages in vitro (reviewed 
in Hayflick, 1998). Insight as to the reason for this apparent paradox was gained by 
Greider and Blackburn (1985), who discovered enzymatic activity in Tetrahynema cell 
extracts that compensated for the incomplete replication of telomere ends. They 
subsequently purified the enzyme and found that it was a riboucleoprotein (RNP) that 
was comprised of an RNA component, as well as a protein component. Thus, they had 
discovered a new type of DNA polymerase, which they named “telomerase” (Greider & 
Blackburn, 1987). Moreover, they discovered that the RNA component contained the 
template required for the addition of nucleotide repeats onto telomeres (Greider and 
Blackburn, 1989). Although all of these findings were in Tetrahymena, it is now known 
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that telomerase provides the main mechanism by which telomeres are elongated in 
eukaryotes. 
            Human telomerase is composed of a reverse transcriptase protein (TERT) 
consisting of 1132 amino acids encoded by the hTERT gene, located on the short arm 
of chromosome 5 (5p15.33). Additionally, it’s composed of telomerase RNA containing 
451 nucleotides encoded by the telomerase RNA gene hTERC, which is located on the 
long arm of chromosome 3 (3q21-q28) (reviewed in Aubert & Lansdorp, 2008). 
Telomerase activity is present in germ cells, stem cells, cancer cells and a subset of 
somatic cells (such as active fibroblasts). However, most somatic cells lack telomerase 
activity, leading them to having a limited life span. In cells lacking telomerase, telomeres 
shorten with each round of cell division, due to the end replication problem. Gradual 
telomere shortening that accompanies cellular proliferation eventually results in 
excessive telomere shortening, leading to the activation of a DNA damage response 
(DDR) at the telomere end, which, in turn, gives rise to permanent growth arrest 
(senescence) (reviewed in Cesare & Reddel, 2008). 
            In addition to averting the end replication problem, telomeres also function to 
prevent chromosomal ends from being distinguished as DNA double strand breaks; 
thereby avoiding the activation of DNA damage signaling pathways and genome 
instability (de Lange, 2009). Ataxia telangiectasia mutated (ATM) kinase pathway and 
ataxia telangiectasia and Rad3 related (ATR) kinase pathway are activated in 
mammalian cells in response to DNA double strand breaks in order to arrest the cell 
cycle and induce apoptosis (programmed cell death). Moreover, homology directed 
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repair (HDR) and non-homologous end joining (NHEJ) repair pathways could also be 
activated to ensure that cells continue dividing with an intact genome. Telomeres 
prevent the effect of these four different pathways by sheltrin. The TRF2 subunit of 
sheltrin is responsible for ensuring that the ATM kinase signaling pathway and NHEJ 
repair pathway are not activated by T-loop formation. On the other hand, POT1 subunit 
is responsible for repressing ATR kinase signaling pathway by preventing RPA, the 
single stranded DNA binding protein, from binding to the telomeric single stranded DNA. 
Both TRF2 and POT1 block the activation of HDR pathway. Failure to do so causes cell 
cycle arrest under the direction of: a) ATM and/or ATR b) chromosome end-to-end 
fusion mediated by NHEJ or c) sequence exchange by HDR involving two telomeres or 
a telomere and another part of the genome.  
            Another problem solved by telomeres is avoiding the loss of valuable genetic 
information, which could occur as a result of a cell’s inability to fully replicate the 
chromatin at the very end of the chromosome. This is prevented by the presence of 
telomere length maintenance mechanism through telomerase (de Lange, 2009). 
Telomere length can also be maintained through a recombination based telomerase-
independent mechanism termed alternative lengthening of telomeres (ALT) (Xu et al., 
2012). 
            Telomere attrition is one of the well-known cell intrinsic events associated with 
normal cellular aging (Mayer et al., 2006). More importantly, telomere attrition and 
dysfunction have been shown to be a causal factor in the acquisition of many age-
related diseases, including, but not limited to atherosclerosis (Bentos et al., 2004); 
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myocardial infarction (Brouilette et al., 2003); Alzheimer’s dementia (Panossian et al., 
2003) and heart failure (reviewed in Oeseburg et al., 2010). Several lifestyle factors 
such as smoking, consumption of unhealthy diet, obesity and lack of exercise can 
accelerate telomere shortening (reviewed in Shammas, 2011). Telomere shortening can 
also occur as a consequence of oxidative damage. Because of their high guanine 
content, telomeres are particularly susceptible to oxidative damage that induces single 
and double DNA strand breaks. Investigators have shown that accumulated single 
strand breaks due to oxidative damage are less efficiently repaired at telomeres than 
any other location in the genome (Shen et al., 2009). Furthermore, interchromosomal 
fusion mediated by excessive telomere shortening can induce genomic instability (de 
Lange, 2005), which, in turn, may contribute to the development of cancer (Meeker, 
2006). Cancer is a term given for a broad group of various diseases where there is 
uncontrolled cell growth. The progression from a normal cell to a cancer cell occurs 
through a number of events in which the cell acquires the so-called “hallmarks of 
cancer” (Hanahan & Weinberg, 2000). Immortality is considered as one of the hallmarks 
of cancer cells. Replicative telomere attrition is considered one of several regulatory 
mechanisms that blocks cell immortality (reviewed in Xu et al., 2012). Replicative 
senescence occurs in a cell after about fifty passages and involves permanent p53-
mediated cell cycle arrest in Gap 1 (G1) phase of the cell cycle  (reviewed in Raynaud 
et al., 2008). However, a DNA damage checkpoint deficient cell can continue dividing 
through p53 or pRb inactivation, resulting in extensive telomere attrition. As a result, 
telomeres lose their protective function allowing frequent chromosomal fusions and 
rearrangements, which lead to massive genomic instability, the latter of which can be 
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lethal for the cell. Cell death is bypassed and immortality is achieved by telomere length 
maintenance through the up-regulation of telomerase in 85% of human tumors 
(Raynaud et al., 2008). In the remaining 15% of human tumors, telomere length is 
maintained by ALT (reviewed in Cesare & Reddel, 2008). Several investigations have 
shown that telomeres are markedly shorter in invasive cancers of the breast, as well as 
its pre-invasive counterparts, despite the presence of telomerase activity (Meeker et al., 
2004).  
            Breast cancer forms in tissues of the breast.  The two main types of breast 
cancer are ductal carcinoma (forms in tubes that carry milk to the nipple) and lobular 
carcinoma (forms in glands that produce milk). Breast cancer may be invasive, meaning 
that it forms in the ducts or lobules and spreads to other tissues of the breast. 
Alternatively, it can be non-invasive, meaning it does not spread to other breast tissues.  
Estrogen receptor positive cancer refers to breast cancer in which the cells have an 
increased sensitivity to estrogen leading to cancer tumor growth. On the other hand, 
HER2- positive breast cancer has an amplification (too many copies) of the HER2 gene, 
which causes the tumor to grow faster and the cancer to be more aggressive. The 
National Cancer Institute estimated the diagnosis of 226,870 new cases of female 
breast cancer and the occurrence of 39,510 deaths in females with breast cancer in 
2012 (most recent estimation). Therefore, breast cancer is considered one of the most 
common malignancies in women, accounting for about 1 in 3 cancers diagnosed among 
females in the United States (DeSantis et al., 2011). However, breast cancer is 
diagnosed in most cases at an early stage (stage I or II). Therefore, 90% of early-
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diagnosed women are expected to survive for at least 5 years (Jemal et al., 2009). 
Patients with breast cancer experience a number of symptoms that tend to cluster with 
each other leading to long-term effects that adversely impact their quality of life (QOL) 
(Dodd et al., 2010). These symptoms, which may manifest from the breast cancer 
treatment and/or the cancer itself, include depression, anxiety (Badger et al., 2007), 
cognitive dysfunction, sleep disturbances, pain and fatigue (Kim et al., 2012). In our 
study, we are collectively naming these symptoms “psychoneurological (PN) 
symptoms”. 
            One-reason patients may present with a number of symptoms, rather than a 
single symptom, is that these symptom “clusters” may share a common biological 
mechanism (Miaskowski & Aouizerat, 2007). Several studies have been conducted in 
order to understand the biological mechanism leading to the development of PN 
symptoms. Symptoms of cancer/cancer treatment are thought to be due, at least in part, 
to cytokine-induced sickness behavior (Cleeland et al., 2003). Cytokines are present in 
increased levels in patients with cancer (Meyers et al., 2005) and can be produced from 
tumor tissues (Sasaki et al., 2001) or in response to chemotherapy (Pusztai et al., 
2004). Although cytokine-induced sickness behavior is considered a reasonable 
mechanism leading to symptom clustering in patients with cancer, it can’t account for all 
the clusters reported to date. This is because several investigators have reported 
different numbers of symptoms in a cluster, as well as different types of symptoms 
within a cluster (Miaskowski and Aouizerat, 2003). Several investigators have shown an 
association between each of the PN symptoms and the activation of inflammation 
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markers, particularly proinflamatory cytokines (reviewed in Kim et al., 2012). However, 
these studies were limited because they focused on single symptoms and single 
markers of inflammation. Moreover, they haven’t clearly explained the mechanism 
leading to the development and persistence of PN symptoms, nor have they given rise 
to innovative therapeutic approaches. 
            Recently, several different mechanisms have been hypothesized to explain the 
association between the development and persistence of PN symptoms and 
inflammation (reviewed in Ahles & Saykin, 2007). Meyers et al. (2005) reported a higher 
than expected incidence of some PN symptoms, as well as proinflammatory cytokines, 
prior to the initiation of chemotherapy. This finding suggests that inflammation may be 
activated by the cancer itself, with the symptoms being worsened by the chemotherapy. 
These findings are of interest because they suggest the need for examining PN 
symptoms associated with chemotherapy within the broader context of biological 
processes associated with the development of cancer; one of which is telomere 
shortening. Acquired telomere attrition has also been speculated to be a causal factor in 
the acquisition of many chronic diseases (Epel et al., 2004). Factors that accelerate the 
rate of telomere shortening include, but are not limited to, chemotherapy (Li et al., 2012) 
and oxidative damage (von Zglinicki, 2002). In fact, in a study by Blasiak et al. (2004) 
higher levels of cellular oxidative damage were observed in women with breast cancer 
when compared to control individuals. Furthermore, a study on leukocytes obtained 
from patients with early stage breast cancer showed a decreased telomere length at five 
and nine months following chemotherapy when compared to baseline values (Schroder 
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et al., 2001). However, information regarding PN symptoms was not integrated into that 
study, since the main focus of these investigators was to determine the effect of stem 
cell transplantation following chemotherapy in the evaluated group of patients. 
            In addition to DNA/chromosomal damage, telomere shortening could contribute 
to PN symptoms by influencing gene expression, since telomeric heterochromatin is 
known to regulate the expression of adjacent subtelomeric genes, which is a 
phenomenon termed  “telomere position effect” (TPE) (Wright & Shay, 1992 ; Ning et 
al., 2003). Given all of the above findings, we opted to study the contributory role of 
telomere shortening in the development and persistence of PN symptoms by measuring 
telomere length in women having breast cancer who received treatment with 
chemotherapy. 
            The gold standard method for measuring telomere length is the terminal 
restriction fragment (TRF) technique. Quantitative Polymerase Chain Reaction (PCR)-
based techniques have also been used in measuring telomere length. However, both 
techniques are limited because they do not provide information on telomere length at 
individual chromosome ends, but instead provide data of average genomic telomere 
length. Moreover, both methods do not allow the recognition of specific chromosomes 
with short telomeres and/or dysfunctional telomeres. Given the limitations of these 
techniques, we chose to measure telomere length using peptide nucleic acid – 
fluorescence in situ hybridization (PNA-FISH), which was developed by Lansdorp et al. 
(1996). This high-resolution technique not only allows the quantification of chromosome-
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specific telomere length, but also provides information about consistent patterns that 
arise in specific chromosomal regions as a result of breast cancer or it’s treatments.  
          The data collected from this study will allow us to test our hypothesis that 
chemotherapy contributes to chromatin breakage leading to telomere shortening. 
One can speculate that telomeric shortening could result in an epigenetic alteration in 
the genes juxtaposed to the telomeric region, giving rise to the development and 
persistence of PN symptoms. Toward this end we propose the following aims: 
Aim 1: To assess chromosome-specific telomere length in cultured lymphocytes 
of women receiving chemotherapy following a diagnosis of breast cancer. 
Aim 2: To determine the correlation between telomere length changes and PN 
symptoms.  
Aim 3: To investigate the correlation between telomere length changes and 
micronuclei (MN) frequency. 
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Chapter 2 
Materials and Methods 
Ascertainment of Samples 
        A total of 25 women with early stage (I to IIIA) breast cancer were ascertained 
through the Massy Cancer Center (MCC) in Virginia Commonwealth University and its 
multiple collaborative sites, including Hematology Oncology Associates of 
Fredericksburg, Inc., Bon Secours Richmond Health System, Peninsula Cancer 
Institute, and Rappahannock General Hospital. To identify potential study participants, a 
member of the research team attended the weekly interdisciplinary Breast Health 
meetings at Virginia Commonwealth University Health System (VCUHS). From the list 
of patients presented at the meeting, those persons meeting the study inclusion criteria 
were identified. The study coordinator then consulted with the attending oncologist and 
with his/her approval approached the patient regarding her desires to participate in the 
study. The offsite research nurses followed similar procedures for identifying potential 
participants at his/her respective site. After providing their informed consent (VCU IRB # 
HM 13194), all participants in this study completed questionnaires and cognitive testing 
via a computerized system at time point one (also referred to as “baseline”, which was 
prior to chemotherapy) and time point two (also referred to as “mid-chemo which was at 
the fourth chemotherapy treatment). During these baseline and mid-chemo visits, blood 
samples (in sodium heparin tube) were collected by venipuncture or an existing access 
device and transported to our laboratory in a biohazard container. The lab staff was 
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blinded to the PN symptom status of the study participants at the time of sample 
processing or evaluation.  
Cell culture, Harvest and Slide Preparation 
        Upon receiving the blood samples, lymphocytes were isolated using Histopaque-
1077 (Sigma). Duplicate stimulated lymphocyte cultures were established and 
harvested using standard procedures [RPMI 1640 media, supplemented with 15% Fetal 
bovine serum (FBS) and phytohemaglutinin (PHA)]. Twenty minutes prior to harvest, 
colcemid (final concentration of 0.1 µg/ml) was added in order to limit microtubule 
formation by inactivating spindle fiber formation, which arrested the cells in metaphase. 
Seventy-two hours after culture initiation, the cultures were harvested as previously 
described (Leach and Jackson Cook, 2001) using standard protocol techniques, 
including a 20 minute incubation in hypotonic solution (0.075 M KCl), a ten minute 
incubation (room temperature) in fixative (3:1 methanol: acitic acid solution) and two 
additional washes in fixative. In order to reduce cytoplasm formation, which can 
compromise probe hybridization, slides were made using a Thermotron, which provided 
a constant temperature (23°C) and humidity (48 ±1°C). A phase contrast/bright field 
microscope was used to ensure that the quality of the slide preparation was optimal for 
the FISH analysis (i.e. enough metaphases present that lacked cytoplasm, had good 
morphology, and were well spread).  The slides were then placed on a hot plate at 60°C 
for an hour, followed by aging at room temperature for 1-2 weeks. Alternatively, after the 
hot plate incubation, the room temperature aging was induced by soaking the slide in a 
2xSSC solution for ten minutes prior to the FISH protocol.  
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Chromosome-Specific Telomere FISH 
        The telomere length of metaphase chromosomes was assessed using a telomere-
specific FITC-labeled peptide nucleic acid (PNA) probe, following the manufacturer’s 
protocol (DakoCytomation, Denmark). Briefly, target slides were soaked in cold fixative 
(3:1 metanol: acitic acid) for one hour. Following air-drying, the slides were rinsed in 
1xTBS (Triss-Buffered Saline, PH 7.5) for two minutes, fixed in 3.7% formaldehyde in 
1xTBS for two minutes, and then rinsed twice in 1xTBS for five minutes each. The 
slides were then immersed in a pre-treatment solution containing proteinase K for ten 
minutes and rinsed twice in 1xTBS for five minutes each. Following dehydration in an 
ethanol series (70%, 85% and 100%) for two minutes each, the slides were air-dried. 
After drying, 22 µl of FITC (CCCTAA)3 labeled PNA probe was added to each full slide 
and a coverslip added. Following the co-denaturation of the probe and metaphase 
chromosomes in a thermocycler at 80°C for three minutes, the slides were hybridized in 
a dry hybridization chamber at room temperature for two hours. Unbound and excess 
probe was then removed by washing in a rinse solution (provided by the manufacturer) 
at room temperature for two minutes, as well as a second wash solution (provided by 
the manufacture) at 65°C for five minutes. After washing, the slides were dehydrated in 
a series of cold ethanol solutions (70%, 85% and 100%) for two minutes each. Finally, 
the slides were air-dried and counterstained with 24 µl of a 5:1 DAPI II /propidium iodide 
(Abott) solution.  
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Telomere Image Analysis 
        A total of ten metaphases for each individual were analyzed using software on an 
Applied Imaging Cytovision system (the Comparative Genomic Hybridization (CGH) 
function) as previously described (Leach et al., 2004). Briefly, for each metaphase 
analyzed, three images were captured using a CCD camera. The first image was 
captured using a DAPI filter to allow for subsequent karyotyping and identification of the 
chromosomes based on their reverse DAPI banding pattern. The second image was 
captured using a FITC filter, which allowed for the visualization of the telomeric probe 
and is termed by the software as the  “test image”. The third image allowed for the 
visualization of the chromosomal bodies based on their propidium iodide stain and is 
termed a “reference image”. Karyograms were prepared for each metaphase spread, 
followed by the designation of the centromere and central axis for each homolog. For 
each telomere, the software compared the fluorescence intensity from the “test image” 
to the fluorescence intensity of the propidium iodide stain in the chromosomal body from 
the “reference image” to generate a ratio profile for each chromosome. For each study 
participant the intensity values were averaged over the twenty homologs from the ten 
metaphase spreads scored. Overlapping chromosomes at the telomere region were 
omitted from the analysis. A representative metaphase is shown in Figure 1.  
Statistical Analysis 
            The total number of females with early stage breast cancer enrolled in this study 
was 25. However, one subject was excluded from the analyses due to the lack of 
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metaphase yield from the blood specimen at mid-chemo. For the remaining participants,  
a paired t- test was used to compare the mean telomere intensity values between 
baseline and post-chemo. Pearson correlation was used to examine the correlation 
between age and telomere length, as well as between PN symptoms and chromosome 
specific telomere intensity values. In order to determine if there was change in the 
telomere intensity value of each chromosomal arm (p arm and q arm) from baseline to 
mid- chemo within and across all study participants, the percent change in telomere 
intensity was obtained using the following formula (for each woman):  
Mid-chemo telomere intensity value - Baseline telomere intensity value 
Baseline telomere intensity value 
A mixed effect model was used to screen multiple variables in this study as predictors of 
the change in telomere length from baseline to mid-chemo. A mixed effect model is 
considered a statistical model that incorporates both fixed effect parameters (which are 
the different variables being tested in this study) and random effects (which are the 
subjects being tested). For all other tests, a p-value of ≤0.05 was considered significant. 
All analyses were performed using JMP software, version 10. Figures were generated 
using R statistical software. 
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Figure 1: A representative image of chromosome-specific telomere FISH. For each 
individual, 10 metaphases were analyzed and for each metaphase 3 images were 
captured. (A) Shows a metaphase spread stained with DAPI, which allows for the 
identification of chromosomes based on reverse DAPI bands. (B) Shows a “test image” 
captured using a FITC filter, which allows the visualization of the telomere probe. (C) 
Represents the “reference image” showing the same metaphase in a PI stain. (D) The 
metaphase as it appears with reverse DAPI bands. (E) Chromosome as it appears in 
the DAPI, FITC labeled and PI image. A representative ratio profile of chromosome 5 
from this cell is shown. For this chromosome the short arm telomere (top of 
chromosome) had a larger fluorescence intensity value (5.0) than the long arm telomere 
(value of 4.13). 
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Chapter 3 
Results 
Sample Distribution  
            The 25 study participants ranged in age from 28 to 69 years old, with an 
average age of 49.84 and a median age of 50 years old. The distribution of the study 
participant’s age is shown in Figure 2. 
Telomere length at baseline and mid-chemo 
            The mean telomere length was estimated for each individual by averaging the 
telomere fluorescent intensity of all chromosomes. Potential correlation between 
telomere length at baseline and age were determined (Table 1). As expected, based on 
previous studies showing that telomere length is inversely correlated with age in the 
general population, a negative correlation between the participants’ age and their 
average telomere length was observed (r= -0.394, p-value=0.0564), as shown in Figure 
3. 
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Figure 2: Age distribution of 25 subjects.  The age range of the study participants (in 
5 year brackets) is shown on the X axis, with the number of women in each age group 
being shown on the Y axis. 
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Table 1: Age and mean telomere length of the 25 study subjects 
 
• Mean telomere length values are the averages of the fluorescent intensities of the 
92 telomeres present in each woman’s genome. 
 
 
 
	   21	  
 
 
Figure 3: Pearson’s correlation between age and mean telomere intensity at 
baseline. Each circle (o) represents a study subject. Mean telomere intensity at 
baseline was negatively correlated with age, with this trend approaching significance (r= 
-0.394, p-value=0.0564).  
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Change of telomere length from baseline to mid-chemo 
            In order to determine if there was change in the telomere intensity value of each 
chromosomal arm (p arm and q arm) from baseline to mid-chemo within and across all 
study participants, the percent change in telomere intensity values were obtained. 
Negative value reflected a decrease in telomere length at the mid-chemo compared to 
baseline time point; a zero value reflected no change in the telomere length; and a 
positive value reflected an increase in the telomere length at the mid-chemo time point.  
The percent change values for each chromosomal telomere (short arm and long arm) 
and each study participant are represented by a heat map (Figure 4). The frequency of 
telomeres showing attrition was higher than the frequency of telomeres showing 
increases in length as indicated by the heat map. In addition to calculating percent 
changes, we compared telomere fluorescent intensities of the short and long arm of the 
23 chromosomes (1-22 and X) between baseline and mid-chemo using a paired t-test. 
A summary of the mean, standard deviation, mean of the difference and p-values are 
shown in Table 2. The majority of chromosomal arms did not show a significant 
difference between baseline and mid-chemo values. However, the short arm of 
chromosome 9 was observed to be significantly shorter in the mid-chemo specimens (p-
value=0.038). In agreement with the t-test results, a significant change in telomere 
length of the short arm of chromosome 9 from baseline to mid-chemo was also detected 
using a mixed effect model analysis  (p-value=0.038). In addition, both the t-test and the 
mixed effect model showed marginal significance for decreases in the telomere lengths 
	   23	  
of the long arm of chromosomes 9, 11, 12, 15 and 18 (t-test p-value = 0.085, 0.080, 
0.065, 0.089, 0.051, respectively).  
 
 
 
 
 
 
	   24	  
Figure 4: Heat map representation of percent changes in telomere intensity 
values from baseline to mid-chemo. Each column represents a chromosomal arm 
and each row represents a study subject. The legend shows the percent change for the 
mid-chemo specimen, with decreases in telomere length being shown in blue tones and 
increases in telomere length being shown in red tones. 
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Table 2: A comparison of telomere intensity values between baseline and mid-
chemo specimens in 24 study participants.  
 
• The p-values indicated are obtained from a t-test. 
• An asterisk is indicative of a significant p-value. 
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Association between chromosome-specific telomere length and 
psychoneurological symptoms 
            To gain insight into the relationship between telomere length and each of the 
seven psychoneurological symptoms evaluated in this study, we performed correlation 
analyses between the score change of each of the symptoms and the percent change in 
telomere intensity values from baseline to mid-chemo for all 92 chromosomal arms. The 
score change was calculated by subtracting the symptom score at baseline from the 
symptom score mid-chemo. Interestingly, there was a significant positive correlation 
between depression and attrition for the telomeres localized to 3p, 3q, 4p, 5q, 6p, 6q, 
10p, 11q, 12p, 12q, 13p, 13q, 14q, 15q, 18p, 18q and 19p (Table 3). Furthermore, even 
with the small sample size in this study, a marginally significant (0.05 < p-value ≤ 0.1) 
positive correlation was observed between the symptom of depression and attrition of 
telomeres localized to 1p, 2p, 7q, 8p, 9q, 16q, 17q, 19q, 20p and Xq (Table 4).    
            In contrast to the correlation between depression and telomere length, no 
significant associations were observed between telomere intensity values and the single 
PN symptoms of pain, fatigue, anxiety, stress and sleep disturbance. The range of 
coefficient correlations and p-values for each symptom evaluated is shown in Table 5. 
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Table 3: Significant correlations between chromosome-specific telomere length 
and depression 
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Table 4: Marginally significant correlations between telomere-specific telomere 
length and depression 
 
• Marginally significant means 0.05 < p-value ≤ 0.1 
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Table 5: Range of correlation coefficients and p-values of the non-significant 
correlations between telomere length and individual psychoneurological 
symptoms 
 
• The correlation coefficients and p-values show the ranges obtained from the 
assessment of correlations between each symptom and each chromosomal arm 
(total of 46 comparisons per symptom). 
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Non-symptom factors influencing telomere length  
            In addition to the assessment of individual PN symptoms, we also investigated 
the relationship (and possible inter-relationship) between telomere length change and 
other variables measured in this study, including (but not limited to) type of 
chemotherapy used in treatment, HER2 status, ER status, and demographic variables 
such as the education level. Screening of these variables, using mixed effect model 
analyses, revealed stress, cognitive functions and chemotherapy as significant 
predictors of changes in telomere length for a subset of specific chromosomal arms 
(Table 6). To tease apart the cognitive component(s) potentially influencing telomere 
length, each of these components were individually evaluated. The individual tests 
showed the memory domain, psychomotor speed domain, reaction time domain, 
complex attention domain, processing speed domain, verbal memory domain and visual 
memory domain to all be significant predictors of the change in telomere length (Table 
7). On the other hand, none of the tumor marker factors or demographic variables 
appeared to be contributory to the change in telomere length (Table 8).  
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Table 6: P-values of the factors predicting the change in telomere length 
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Table 7: P-values of cognitive function components as predictors of the change 
in telomere length 
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Table 8: Range of p-values of psychoneurological symptoms and non-symptom 
factors evaluated that showed no significant effect as potential predictors of the 
change in telomere length  
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Association between micronuclei frequency and telomere length 
            In an effort to investigate the relationship between micronuclei formation, as an 
indicator of chromosomal instability, and telomere length attrition we compared 
micronuclei frequencies and telomere length intensity values using a Pearson 
correlation test. No significant association was observed between telomere length 
attrition (indicated by the percent change) and micronuclei frequency [(r ranging from -
0.197 to 0.235) and a p-value ranging from 0.268 to 0.979. In addition, we performed a 
mixed effect model analysis using the raw data, which showed micronuclei frequency 
was not a significant predictor of the change in telomere length (p-value ranging from 
0.091 to 0.996).  
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Chapter 4 
Discussion and Future Directions 
Discussion 
            The purpose of this current work was to assess telomere length in women with 
early stage breast cancer who were treated with chemotherapy in order to determine if 
chemotherapy influenced telomere length and if telomere length is related to the 
development and persistence of PN symptoms. To test our hypothesis that 
chemotherapy contributes to chromatin breakage leading to telomere shortening, 
we determined chromosome-specific telomere lengths before treatment and at the mid-
point of chemotherapy treatment.  Consistent with previous studies, our data showed a 
significant (marginally so in our small sample) negative correlation between age and 
telomere length. When determining the percent change in telomere length of each 
chromosomal arm from baseline to mid-chemo, we observed telomere shortening for 
the majority of chromosomal arms in the majority of study subjects. Several factors may 
have contributed to this change. First, being triple guanine containing structures, 
telomeres are highly sensitive to damage by oxidative stress. Therefore, high intensity 
stress, such as that seen from the cancer itself or its treatment, can accelerate telomere 
shortening by inducing a high frequency of DNA double strand breaks. Furthermore, 
oxidative damage contributes to telomere shortening more than that caused by the end 
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replication problem (reviewed in von Zglinicki, 2002). Thus, since patients with breast 
cancer have higher levels of oxidative damage than control individuals (Blasiak et al., 
2004), the presence (or increase) in reactive oxidative molecules may have contributed 
to the telomere shortening observed in these patients. Stress also results in activation of 
the HPA axis, which initiates a cascade of changes involving molecules. One effect of 
the stress activation pathway is activation of cytokines such as interleukin 2 (IL-2), (IL-
6), (IL-8) and (IL-10). Interestingly, chemotherapy has also been associated with higher 
levels of (IL-6), (IL-8) and/or (IL-10) (reviewed in Seruga et al., 2008). Moreover, the 
above-mentioned cytokines where found at higher levels in serum samples of patients 
with breast cancer compared with controls (Lyon et al., 2008). Increased inflammatory 
activity can accelerate telomere attrition in leukocytes by inducing cell turnover and 
replicative senescence (Aviv, 2004) or by enhancing the release of reactive oxygen 
species (ROS) that shortens and damages telomeres through oxidative stress (Jaiswal 
et al., 2000). A third factor that might induce rapid telomere DNA sequence loss is 
chemotherapy, which will be discussed in a later part (Li et al., 2012).  
            While the majority of telomeres showed shortening, some telomeres showed 
gains in length at the mid-chemo compared to baseline time point. One can speculate 
that this finding could be attributed to epigenetic alterations, which are known 
modulators of telomere length (reviewed Blasco, 2007). For example, CCCTC-binding 
factor (CTCF) is a chromatin insulator protein, which is known to be a negative regulator 
and an inhibitor of hTERT gene expression. CTCF is regulated by another gene, called 
brother of the regulator of imprinted sites (BORIS), which codes for a protein that 
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inhibits CTCF and is detected at high levels in leukocytes of patients with breast cancer 
compared with controls (D'Arcy et al., 2006). Therefore, by inhibiting the binding of 
CTCF to hTERT, the activity of BORIS could be epigenetically regulated to influence 
telomere length.  
            The use of a chromosome specific approach to assess telomere length allowed 
us to detect a significant shortening of telomere length on the short arm of chromosome 
9 from baseline to mid-chemo. Telomere shortening on the short arm of chromosome 9 
could be an early event, as it has been recognized in previous studies of breast cancer 
risk (Zheng et al., 2009). Telomere dysfunction and/or loss of the short arm of 
chromosome 9 could lead to increased chromosomal instability for that specific 
chromosomal arm, which, in turn, could result in an increased susceptibility for 
chromosome 9 deletions. The short arm of chromosome 9 (9p21) contains a tumor 
suppressor gene CDKN2A. This gene encodes p16INK4 and p14IRF proteins, which are 
involved in the regulation of the TP53 and retinoblastoma (RB) pathways, the latter of 
which are considered to play an important role in breast tumor chromosomal instability. 
Thus, it is feasible that this 9p telomeric attrition is either directly, or indirectly, leading to 
imbalances that could impact cellular function. We also found a marginally significant 
decrease involving the telomeres of the long arm of chromosomes 9, 11, 12, 15 and 18 
at the mid- chemotherapy time point. While it is likely that the paucity of chromosome-
specific telomeres showing attrition is attributable to the small sample evaluated in this 
study, there is also a possibility that the lack of significant shortening in telomere length 
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at the mid-chemo time point is due to insufficient toxicity of the treatment to elicit 
telomeric shortening in the cells.  
            One important aspect of this study was to investigate the contributory role of 
telomere shortening to the development and persistence of PN symptoms. By 
performing correlation studies between telomere shortening in our study participants 
and the different PN symptoms, we observed a significant positive correlation between 
telomere shortening and depression. Once again, in many studies of depression, 
significant increases of oxidative stress (Ng et al., 2008) and inflammation (Dinan, 2008) 
have been reported. However, the direction of causality in this purported relationship 
cannot be determined since lymphocytes with shortened telomeres hyper-secrete 
proinflammatory cytokines, particularly IL-6 (Effros, 2009). While elevated, IL-6 levels in 
patients having depression have been noted to be comparable in women with or without 
breast cancer (Musselman et al., 2001). High levels of IL-6 can induce “sickness 
behavior”, which includes depression as one of its symptoms. However, given that the 
IL-6 molecule is labile (not retained for long periods of time), its effects may be indirect. 
While the biological cascade of events is not known, one can speculate that telomere 
shortening may lead to chromosomal instability or perturbations in gene expression and 
that these genetic imbalances could then contribute to depressive symptoms that 
develop in these patients.  
            In an effort to understand the relationship between telomere shortening and the 
demographic and behavioral variables measured in this study, we analyzed the ability of 
these variables to predict the changes seen in telomere length. These tests identified 
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stress, cognitive function and chemotherapy as predictors of the change in telomere 
length. Unexpectedly, our mixed effect model suggests that patients with higher scores 
on the perceived stress scale (PSS) tended to have longer telomere lengths whereas 
those with higher scores of cognitive function tended to have shorter telomere lengths. 
The inconsistency of these results with previous studies in the literature could be 
attributed to our small sample size. Alternatively, the PSS employed in this study may 
have captured only the most recent stress events, with the length of the telomere being 
influenced by both current and past stress events. As for the cognitive findings, the 
metrics that have been used in our study to measure the level of cognitive function have 
been noted to have some mathematical inconsistencies that may contribute to this 
observation. Thus, the predictive relationship with cognitive function is considered to be 
a tentative finding until the questions regarding the measurements have been resolved. 
In contrast, the observed relationship between chemotherapy and telomere length does 
not appear to be confounded by methodological factors. Thus, we were able to 
conclude that chemotherapy is a negative predictor of the change in telomere length 
(chemotherapy leads to shortening of telomeres). Previous work that has been done by 
Li and colleagues (2012) strongly supports our observation. Chemotherapeutic agents 
can contribute to telomere loss by the inhibition of hTERT expression, which in turn 
reduces telomerase activity. Chemotherapy can also affect telomere length through an 
effect on telomere-associated proteins (POT1 and TPP1). POT1 binds the single 
stranded 3’ overhang and suppresses unwanted DNA repair activities. It recruits TPP1, 
which directly interacts with telomerase for its recruitment to the telomere. Furthermore, 
TPP1 enhances the affinity of POT1 to the telomeric DNA. Therefore, a reduced 
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expression of these proteins by chemotherapeutic agents could alter the telomere 
structure and compromise it’s stability, thereby leading to telomere shortening. 
Doxorubicin (DOX) is a widely used chemotherapeutic drug that is known to interact 
with the DNA by intercalation and induce DNA double strand breaks (Rossi et al., 2003). 
Therefore, telomere shortening may also be a consequence of this form of action due to 
increased cell replication mediated by multiple cycles of injury and repair (Li et al., 
2012). Furthermore, DOX may play a major role in telomere shortening by producing 
free radicals that cause direct oxidative damage to the DNA (Quiles et al.,  2002).  
            The quantification of micronuclei (MN) frequencies in lymphocytes of patients 
with cancer has been used extensively as a biomarker of chromosomal damage and 
genomic instability. Indeed, in our study participants, MN frequencies have been shown 
to be significantly higher than those of controls at baseline levels. In addition, the MN 
frequencies at the mid-chemo time point are significantly higher than those seen at 
baseline (Aboalela, 2012). Given that telomeric attrition has been associated with an 
increased frequency of chromosomal instability and that general chromosomal instability 
is correlated with MN frequencies, we expected to see a negative correlation between 
telomere length and micronuclei frequencies (shorter telomeres leading to higher MN 
levels). However, no clear association was detected. One explanation for this 
observation is that the sample size is too small to allow for the detection of a significant 
relationship between these two variables. However, it is also quite feasible that while 
aberrations related to telomeric attrition following chemotherapy may arise, the majority 
of the large number of chromosomal changes being induced by chemotherapy may 
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occur at sites other than the telomere. This latter explanation is consistent with our 
observation of an increase in MN at mid-chemo, but a lack of association with telomere 
length change. In conclusion, this study shows that telomere length is shortened after 
treatment with chemotherapy on the majority of chromosomal arms. Our use of a 
chromosome specific telomere assay allowed the recognition that this shortening does 
not affect all telomeres equally, since only a subset of telomeres were most impacted. In 
particular, the short arm of chromosome 9 was observed to show the greatest attrition 
response. Furthermore, we showed a negative correlation between telomere length and 
depression and a negative effect of chemotherapy on the telomere length. While 
preliminary, these results support our hypothesis that treatment with chemotherapy 
triggers telomere shortening, which in turn plays a role in the development of PN 
symptoms.  
Future directions 
            This study is designed to assess telomere length in women with breast cancer 
who are treated with chemotherapy, with the goal of improving our understanding of the 
role biological events play in the development and persistence of PN symptoms. Data 
analysis using a mixed effect model to identify predictors of the change in telomere 
length showed partial inconsistency with the literature. In addition, we noticed an issue 
with the metrics used for the determination of cognitive function scores. Therefore, it is 
important to test the reproducibility of our results by increasing the sample size and re-
evaluating the accuracy and reliability of the metrics used for the measurement of PN 
symptoms.  Our future studies will involve assessments of more patients (for a total of 
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75 women), as well as evaluations of additional time points (6 months, 1 year and 2 
years post-chemotherapy). By increasing our observations the expanded longitudinal 
study is expected to provide new insights regarding the relationship between telomere 
shortening and the acquisition/persistence of PN symptoms in women receiving 
chemotherapy treatment following their diagnosis of BC. Given that many women are 
living years after their treatments, this knowledge is important to allow for the 
recognition of therapeutic and intervention strategies that will be most effective in 
alleviating their adverse side effects and for ultimately improving their quality of life. 
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